目的 探讨千层纸素A抑制宫颈癌的作用及潜在机制。方法 在GEO和TCGA数据集中分析SHC SH2结构域结合蛋白1（SHCBP1）在宫颈癌患者与健康人之间的表达的差异；通过MTT实验验证千层纸素A对HeLa细胞的抑制作用。采用Western blotting实验对千层纸素A与SHCBP1之间关系进行研究，运用分子模拟对接评估千层纸素A与SHCBP1蛋白的对接效果；Linkedomics分析宫颈癌患者中SHCBP1的共表达基因；基因本体（GO）和京都基因组百科全书（KEGG）分析相关共表达基因的潜在机制；CIBERSORT法分析SHCBP1与宫颈癌免疫细胞浸润的相关性；TISIDB数据库分析SHCBP1与免疫检查点的关系。结果 GEO数据库及TCGA数据库的分析结果得出，SHCBP1在宫颈癌患者中显著高表达；MTT和Western blotting分析结果显示，千层纸素A在10 μmol/L即对HeLa细胞增殖和SHCBP1的表达具有显著的抑制效果（P＜0.05）。分子对接结果显示，千层纸素A与SHCBP1具有较好的结合势能；TISIDB数据库的研究及CIBERSORT法对GEO数据集的分析结果得出，SHCBP1参与了宫颈癌细胞的免疫浸润；SHCBP1及其共表达基因主要富集于炎症相关途径中。结论 千层纸素A通过抑制SHCBP1介导的免疫浸润来抑制宫颈癌的生长，这可能在宫颈癌的治疗中有重要意义。

Objective To investigate the inhibitory effect and potential mechanism of oroxylin A on cervical cancer. Methods The expression difference of SHCBP1 between cervical cancer patients and healthy people was analyzed in GEO and TCGA datasets. The inhibitory effect of oroxylin A on Hela cells was verified by MTT assay. Western blotting experiments were used to study the relationship between oroxylin A and SHCBP1, and molecular simulation docking was used to evaluate the docking effect between oroxylin A and SHCBP1. The co-expression gene of SHCBP1 in patients with cervical cancer was analyzed by Linkedomics. Gene Ontology (GO) and Kyoto Genome Encyclopedia (KEGG) were used to analyze the underlying mechanisms of related co-expressed genes. CIBERSORT method was used to analyze the correlation between SHCBP1 and immune cell infiltration of cervical cancer. TISIDB database was used to analyze the relationship between SHCBP1 and immune checkpoint. Results The analysis results of GEO database and TCGA database showed that SHCBP1 was highly expressed in cervical cancer patients. The results of MTT and Western blotting analysis showed that oroxylin A had significant inhibitory effect on the expression of Hela cells and SHCBP1 at the concentration of 10 μmol/L (P< 0.05). The results of molecular docking showed that the combination of oroxylin A and SHCBP1 had good potential energy. The results of TISIDB database and CIBERSORT analysis of GEO data show that SHCBP1 is involved in the immune invasion of cervical cancer cells. SHCBP1 and its co-expression genes are mainly enriched in inflammatory pathways. Conclusion Oroxylin A suppresses the growth of cervical cancer by suppressing SHCBP1-mediated immune infiltration, which could potentially have significant implications in the treatment of cervical cancer.

R285；R979.1